Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol | Zendy

Ditte Hansen | Zendy; Knud Rasmussen | Zendy; Susanne S. Pedersen | Zendy; Lars Melholt Rasmussen | Zendy; Lisbet Brandi | Zendy

Open Access

Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol

Author(s) -

Ditte Hansen,

Knud Rasmussen,

Susanne S. Pedersen,

Lars Melholt Rasmussen,

Lisbet Brandi

Publication year - 2011

Publication title -

nephrology dialysis transplantation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.654

H-Index - 168

eISSN - 1460-2385

pISSN - 0931-0509

DOI - 10.1093/ndt/gfr668

Subject(s) - paricalcitol , alfacalcidol , medicine , secondary hyperparathyroidism , fibroblast growth factor 23 , hyperparathyroidism , endocrinology , kidney disease , vitamin d and neurology , calcitriol , urology , parathyroid hormone , calcium , osteoporosis , bone mineral

Fibroblast growth factor 23 (FGF23) increases renal phosphate excretion and decreases the formation of 1,25 dihydroxyvitamin D. In patients with chronic kidney disease, plasma FGF23 levels are markedly elevated by unknown mechanisms. We explored the changes in FGF23 during treatment of secondary hyperparathyroidism (SHPT) with alfacalcidol or paricalcitol in haemodialysis patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research